Source: http://www.readbag.com/accessdata-fda-cdrh-docs-pdf4-k043218
Timestamp: 2019-08-18 00:36:32
Document Index: 602997154

Matched Legal Cases: ['arts 800', 'art 807', 'arts 801', 'art 820', 'art 807', 'art-21']

Read K043218.pdf
Read K043218.pdf text version
/ -tj'3 J
510(k) Premarket Notification; ABL800 FLEX with FLEXQ Module MAY 1, 0 2005
RADIOMETERr` COPENHAGEN1'Il
510(k) Summary - ABL800 FLEX with FLEXQ Module
Submitter: Address: Phone: Fax: Contact Person: Date Summary Prepared: Device Trade Name: Common name: Classification Name: Radiometer Medical ApS Akandevej 21, DK-2700 Bronshoj, Denmark +45 3827 3827 or +45 3827 3390 (direct) +45 3827 2736 Ms. Kirsten Rono November 19, 2004
ABL800 FLEX with FLEXO Module Blood Gas, Co-oximetry, Electrolyte and Metabolite Analyzer Blood gases and blood pH test system (21 CFR Section 862.1120)
RADIOMETER ABL800 FLEX (K041874) and AVL 9181 Electrolyte Analyzer (K972673).
The ABL800 FLEX with FLEXO Module is an ABL800 FLEX Analyzer with the added optional capability of automatic sampling from of up to three blood samplers. Thus, the analyzer part of the ABL800 FLEX with FLEXO is identical to the analyzer part of the ABL800 FLEX. As with the ABL800 FLEX, the ABL800 FLEX with FLEXO Module consists of several models of the same analyzer for the measurement of blood gas, electrolyte, metabolite and co-oximetry. The FLEXQ module is designed to work with the vented arterial blood sampler, safePICO (subject of a separate 510(k) application). In the sampler barrel the safePICO includes a magnetic steel ball that may be activated by the FLEXO module for automatically mixing the sample before measurement. On the outside of the barrel, each safePICO sampler has a unique barcode that may be read by the FLEXQ module. The safePICO sampler is delivered with a new vented tip cap that allows the sampler to be vented after the appliance of the tip cap to the sampler. The sample is introduced into the analyzer by the inlet probe of the ABL800 FLEX Analyzer penetrating the top of the tip cap and entering the sampler. Installing a FLEXQ module into an existing ABL800 FLEX Analyzer includes physically installing the module and loading upgraded software, which controls the function of the FLEXO module. The FLEXO module comprises a sampler tray with three slots for holding up to three samplers simultaneously. Each slot has an optical switch detecting the presence of a sampler. The FLEXO module has a barcode reader, which can read out the barcode of the samplers. Further, the FLEXQ module includes a rotating magnet system located under the sampler tray, which interacts with the steel ball in the sampler barrel and thus automatically mixes the sample prior to measuring.
0000?3
510(k) Premarket Notification; ABL800 FLEX with FLEXQ Module
RADIOMETERV
COPENHAGENR:1
Example of automatic queuing and analyzing a sample: When a blood sample has been performed as prescribed with the safePICO sampler, the sampler is provided with the vented tip cap on the syringe luer tip and arranged in a free slot of the FLEXQ sampler tray. The presence of the sampler is detected and the barcode of the sampler is read out. The sampler is now put in queue to be analyzed. When the analyzer is ready to analyze the blood sample, the magnet system is activated to rotate and move the steel ball in the sampler in approximately 5 seconds to mix the sample. The sampler tray is then displaced to position the sampler in front of the inlet of the analyzer. The inlet probe of the analyzer penetrates the top of the tip cap and enters the sample barrel to aspirate the blood sample into the analyzer. The sample is then analyzed and the sampler may be removed and discarded as prescribed. The upgraded software controls all steps of the FLEXQ module and the ABL800 FLEX Analyzer. Ifrequired, manual introduction of a blood sample may be performed as well. This may be relevant when having only small sample volumes e.g. in capillary tubes, or ifit becomes necessary to perform an urgent measurement when all three slots of the FLEXQ sample tray are occupied.
The ABL800 FLEX with FLEXQ Module is intended for in vitro testing of samples of whole blood for the parameters pH, P0 2, PCO2, potassium, sodium, calcium, chloride, glucose, lactate, total bilirubin, and co-oximetry parameters (total hemoglobin, oxygen saturation, and the hemoglobin fractions FO Hb, FCOHb, FMetHb, FHHb and FHbF) as well as for in vitro 2 testing of samples of expired air for the parameters P0 2 and PC02.
Statement of Indication for Use
Indication for use information for the analytes measured by the ABL800 FLEX with FLEXQ Module: pH: pH is the indispensable measure of acidemia or alkalemia and is therefore an essential part of the pH/blood gas measurement. The normal function of many metabolic processes requires a pH to be within a relatively narrow range. pO2: The arterial oxygen tension is an indicator of the oxygen uptake in the lungs.
pCO 2 : PCO2 is a direct reflection of the adequacy of alveolar ventilation in relation to the
metabolic rate. Potassium (cK+): The measurements of the concentration of potassium ions in plasma are used to monitor the electrolyte balance.
COPENHAGEN OI
Sodium (cNa+): The measurements of the concentration of sodium ions in plasma are used to monitor the electrolyte balance. Calcium (cCa2+): The measurements of the concentration of calcium ions in plasma are used to monitor the electrolyte balance. Chloride (cCl'): The measurements of the concentration of chloride ions in plasma are used to monitor the electrolyte balance. Glucose (cGlu): The glucose measurements measure the concentration of glucose in plasma. The glucose measurements are used to screen for, diagnose and monitor diabetes, pre-diabetes, and hyper- and hypoglycemia. Lactate (cLac): The lactate measurements measure the concentration of lactate in plasma. Lactate measurements serve as a marker of critical imbalance between tissue oxygen demand and oxygen supply. Bilirubin (ctBil): The bilirubin measurements measure the total concentration of bilirubin in plasma. ctBil is used to assess the risk of hyperbilirubinemia. Total Hemoglobin (ctHb): ctHb is a measure of the potential oxygen-carrying capacity of the blood. Oxygen Saturation (sO2): sO2 is the percentage of oxygenated hemoglobin in relation to the amount of hemoglobin capable of carrying oxygen. sO2 allows evaluation of oxygenation. Fraction of Oxyhemoglobin (FO2Hb): FO2Hb is a measure of the utilization of the potential oxygen transport capacity; that is the fraction of oxyhemoglobin in relation to all hemoglobins present (tHb) including dyshemoglobins. Fraction of Carboxyhemoglobin (FCOHb): FCOHb is the fraction of carboxyhemoglobin. It is incapable of transporting oxygen. Fraction of Methemoglobin (FMetHb): FMetHb is the fraction of methemoglobin. It is incapable of transporting oxygen. Fraction of Deoxyhemoglobin in Total Hemoglobin (FHHb): FHHb is the fraction of deoxyhemoglobin in total hemoglobin. Itcan bind oxygen then forming oxyhemoglobin. Fraction of Fetal Hemoglobin (FHbF): Fetal hemoglobin consists of two a-chains and two 13-chains, and has a higher oxygen affinity than adult Hb.
510(k) Premarket Notification; ABL800 FLEX with FLEXQ Module I~. RADIOMETER
COPENHAGEN'
510(k) Summary - ABL800 FLEX with FLEXQ Module Clinical Interpretation
Clinical interpretation for the analytes measured by the ABL800 FLEX with FLEXQ Module: pH: Common causes of low pH (acidosis) may be A)respiratory acidosis as alveolar hypoventilation or increased metabolic rate or B) metabolic acidosis as circulatory impairment, renal failure, diabetic ketoacidosis or gastro-intestinal loss of bicarbonate (diarrhea). Common causes of high pH (alkalosis) may be A)respiratory alkalosis as alveolar hyperventilation or B) metabolic alkalosis as diuretics, gastrointestinal loss of acid (vomiting) or hypokalemia (low cK+).
p02: Common causes of low P 0 2 is pulmonary disease, cardiac right to left shunt, low
alveolar ventilation and ambient pressure.
pC0 2 : Common causes of low pCO2 (alveolar hyperventilation - hypocapnia) may be A)
aggressive ventilator treatment or psychogenic hyperventilation or B) compensatory to metabolic acidosis, secondary to central nervous system affection or secondary to hypoxia. Common causes of high pCO 2 (alveolar hypoventilation - hypercapnia) may be lung disease, central nervous system depression, either primary, or secondary to sedation or analgesics or ventilator treatment, either with strategy of permissive hypercapnia or with too low alveolar ventilation. Potassium (cK+): Common causes of low cKt may be diuretics, diarrhoea, vomiting, respiratory or metabolic baseosis or hyperaldosteronism. Common causes of high cK* may be renal failure, metabolic acidosis or toxic acidosis (salicylate, methanol, etc.). Sodium (cNa+): Common causes of low values of cNa* may be water intoxication, renal failure, heart failure, liver failure, increased ADH secretion, diuretics or nephrotic syndrome. Common causes of high values of cNa + may be increased Na-toad, Steroids, vomiting, diarrhea, excessive sweating or osmotic diuresis. Calcium (cCa 2+): Common causes of low values of cCa 2* may be baseosis, renal failure, acute circulatory insufficiency, lack of vitamin D or hypoparathyroidism. Common causes of high values of cCa 2+ may be malignancies, thyreotoxicosis, pancreatitis, immobilization or hyperparathyroidism. Chloride (cCl-): Common causes of low cCl may be primary metabolic acidosis or a secondary metabolic acidotic compensation for respiratory alkalosis. Common causes of high cCP may be metabolic alkalosis either as primary disorder of as compensation for chronic respiratory acidosis. Glucose (cGlu): Common causes of low cGlu may be insulin overdose, adrenal insufficiency and extensive liver disease. Common causes of high cGlu may be lack of insulin, acute stress (response to trauma, heart attack, and stroke).
RADIOMETERME
COPENHAGENL9VA
Lactate (cLac): In most situations, elevated blood lactate will be caused by hypoperfusion, severely impaired arterial oxygen supply, or a combination of the two. Decreasing or persistently low levels of blood lactate (cLac) during critical illness signal successful treatment. Bilirubin (ctBil): Bilirubin is formed as a result of the catabolism of hemoglobin. Typically, the major part of bilirubin in plasma comes from the breakdown of red cells. Neonates have an increased breakdown of hemoglobin, limited hepatic function and low concentrations of albumin. Ifthe concentration of bilirubin in neonates exceeds defined levels it requires specific therapy. Total Hemoglobin (ctHb): High values of ctHb typically indicate a high blood viscosity, which increases the afterload to the heart and thereby can cause forward failure. In extreme cases, the microcirculation can be impaired. Common causes of high values of ctHb (polycytemia) may be A) polycytemia vera or B)dehydration, chronic lung disease, chronic heart disease, living at high altitude or trained athletes. Low concentrations of total hemoglobin or effective hemoglobin imply a risk of tissue hypoxia because of the lowered arterial oxygen content (ctO2). Common causes of low values ctHb (anemia) may be A) impaired red cell production or B) hemolysis, bleeding, dilution (overhydration) or multiple blood samples (neonates). Oxygen Saturation (sO2): High (normal) s0 2 may be a measure of sufficient utilization of actual oxygen transport capacity. Common causes of low s02 may be impaired oxygen uptake. Fraction of Oxyhemoglobin (FO2Hb): High (normal) FO2Hb may be an indication of sufficient utilization of oxygen transport capacity. Common causes of low FO2Hb may be impaired oxygen uptake or presence of dyshemoglobins. Fraction of Carboxyhemoglobin (FCOHb): FCOHb levels are normally below 2 %, but heavy smokers may have up to 9-10 %. Newborns may present up to 10-12 % of FCOHb because of an increased hemoglobin turnover combined with a less developed respiratory system. In the acute exposition, headache, nausea, dizziness and chest pain occur with 1030 %. Severe headache, general weakness, vomiting, dyspnea and tachycardia occur at 3050 %. Above 50 %, seizures, coma and death occur. Fraction of Methemoglobin (FMetHb): FMetHb levels above 10-15 % can result in pseudocyanosis. Methemoglobinemia may cause headache and dyspnea at levels above 30 % and may be fatal, especially in levels above 70 %. Fraction of Deoxyhemoglobin in Total Hemoglobin (FHHb): FHHb is an expression of the amount of hemoglobin not bound to oxygen, but capable of being bound to oxygen ifthe oxygen supply is increased.
0000?7
RADIOMETERE COPENIHAGEN' r'V
Fraction of Fetal Hemoglobin (FHbF): FHbF indicates the amount of fetal hemoglobin. FHbF is seldom used clinically.
Comparison tests verifying that the ABL800 FLEX with FLEXQ Module performs equivalent to the predicate devide ABL800 FLEX (Kg41874) will be performed.
The measuring technology of the ABL800 FLEX with FLEXQ Module includes electrochemical and optical technology. The sensors for measuring blood gases and pH, sodium, potassium, calcium, chloride, glucose and lactate are electrochemical sensors. The electrochemical sensors are based on potentiometric and amperometric methods. The optical system of the ABL800 FLEX with FLEXQ Module for measuring co-oximetry parameters and bilirubin includes a 128-wavelength spectrophotometer. The system is based on absorbance measurements. The FLEXQ module automates the inlet of sample including reading of sample IDand mixing of the sample. The module has a sampler tray with three sampler slots, a barcode reader and a sample mixing system comprising a rotating magnet system. The ABL800 FLEX with FLEXQ Module may be interfaced with the RADIANCE STAT analyzer management system software as well as with the hospital LIS/HIS systems through network interfaces. The ABL800 FLEX with FLEXQ Module is similar in technological characteristics, device performance and intended use as the predicate devices and is therefore substantially equivalent to the predicate devices.
Summary of Technological Characteristics
The ABL800 FLEX with FLEXQ Module is substantially equivalent in features and characteristics to the predicate devices, ABL800 FLEX (K041874) and AVL 9181 Electrolyte Analyzer (K972673).
MAY ] 0 2005
Ms. Lene Meineche Marnes Regulatory Affairs Radiometer Medical Aps Akandevej 21 Bronshoj Denmark DK-2700
k043218 Trade/Device Name: ABL800 FLEX with FLEXQ Module Regulation Number: 21 CFR 862.1120 Regulation Name: Blood gases (pCO 2, pO2) and blood pH test system Regulatory Class: Class II Product Code: CHL, JGS, CEM, JFP, CGZ, CGA, KHP, CIG, MQM, GHS, GKR, KQI Dated: March 11, 2005 Received: March 16, 2005
Dear Ms. Marnaxs: We have reviewed your Section 5 10(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
Page 2 This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled, &quot;Misbranding by reference to premarket notification&quot; (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.htmI Sincerely yours,
I '~J'~' cAA~~~,-A6
I&quot;&quot;
~~~11 lean M. Cooper, MS, D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
510(k) Number: Device Name: ,
ABL800 FLEX with FLEXQ Module
Intended Use: The ABL800 FLEX with FLEXQ Module is intended for in vitro testing of samples of whole blood for the parameters pH, P0 2, pCO 2, potassium, sodium, calcium, chloride, glucose, lactate, total bilirubin, and co-oximetry parameters (total hemoglobin, oxygen saturation, and the hemoglobin fractions FO2Hb, FCOHb, FMetHb, FHHb and FHbF) as well as for in vitro testing of samples of expired air for the parameters PO2 and pCO 2. Indications For Use: Indication for use information for the analytes measured by the ABL800 FLEX: pH: pH is the indispensable measure of acidemia or alkalemia and is therefore an essential part of the pH/blood gas measurement. The normal function of many metabolic processes requires a pH to be within a relatively narrow range. PO2: The arterial oxygen tension is an indicator of the oxygen uptake in the lungs.
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign-W Office of In Vitro Diagnostic Device Evaluation and Safety 810(k)
k ('A '2 )SZ\
oooo1(
RADIOMETERW~GOPENHAGEN OWa
PC0 2: pCO 2 is a direct reflection of the adequacy of alveolar ventilation in relation to the
Potassium (cK4): The measurements of the concentration of potassium ions in plasma are used to monitor the electrolyte balance. Sodium (cNa'): The measurements of the concentration of sodium ions in plasma are used to monitor the electrolyte balance. Calcium (CCa 2 l): The measurements of the concentration of calcium ions in plasma are used to monitor the electrolyte balance. Chloride (cClj: The measurements of the concentration of chloride ions in plasma are used to monitor the electrolyte balance. Glucose (cGlu): The glucose measurements measure the concentration of glucose in plasma. The glucose measurements are used to screen for, diagnose and monitor diabetes, pre-diabetes, and hyper- and hypoglycemia. Lactate (cLac): The lactate measurements measure the concentration of lactate in plasma. Lactate measurements serve as a marker of critical imbalance between tissue oxygen demand and oxygen supply. Blifrubin (ctBiI): The bilirubin measurements measure the total concentration of bilirubin in plasma. ctBil is used to assess the risk of hyperbilirubinemia.
Division Sign-iff Office of InVitro Diagnostic Device Evaluation and Safety 51 0(k)
~~~Page 2of 3
Y:iA 32,w
UUUU2L
RADIOMETERVI-V
COPENHAGEN:INV
November 19, 2004 Total Hemoglobin (ctHb): ctHb is a measure of the potential oxygen-carrying capacity of the blood. Oxygen Saturation (sO 2): sO2 is the percentage of oxygenated hemoglobin in relation to the amount of hemoglobin capable of carrying oxygen. sO2 allows evaluation of oxygenation. Fraction of Oxyhemoglobin (FO2Hb): FO2Hb is a measure of the utilization of the potential oxygen transport capacity; that is the fraction of oxyhemoglobin in relation to all hemoglobins present (tHb) including dyshemoglobins. Fraction of Carboxyhemoglobin (FCOHb): FCOI-b is the fraction of carboxyhemoglobin. It is incapable of transporting oxygen. Fraction of Methemoglobin (FMetHb): FMetHb is the fraction of methemoglobin. It is incapable of transporting oxygen. Fraction of Deoxyhemoglobin in Total Hemoglobin (FHHb): FHHb is the fraction of deoxyhemoglobin in total hemoglobin. It can bind oxygen then forming oxyhemoglobin. Fraction of Fetal Hemoglobin (FHbF): Fetal hemoglobin consists of two a-chains and two P-chains, and has a higher oxygen affinity than adult Hb.
(Part-21 CFR 801 Subpart D)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Page 3 of 3 Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety